FindTrial
Sign In

solution à diluer pour solution injectable/pour perfusion

DRUG3 trials

Sponsors

Celgene Corp., Cabaletta Bio Inc., Centre Hospitalier Universitaire De Lille

Conditions

Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLENewly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell TransplantationPatients (male or female) ≥18 years old with R/R AML that expresses CD19 by Flow-cytometrywhich can lead to significant morbidity and mortality.

Phase 1

A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
RecruitingCTIS2023-507613-10-01
Cabaletta Bio Inc.Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLE, which can lead to significant morbidity and mortality.
Start: 2025-03-31Target: 6Updated: 2026-01-26
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML expressing CD19.”
RecruitingCTIS2023-509212-29-01
Centre Hospitalier Universitaire De LillePatients (male or female) ≥18 years old with R/R AML that expresses CD19 by Flow-cytometry
Start: 2025-07-10Target: 5Updated: 2025-10-20

Phase 3

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Active, not recruitingCTIS2022-501346-30-00
Celgene Corp.Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell Transplantation
Start: 2023-09-25Target: 332Updated: 2025-12-09